Zymeworks Inc.
ZYMEHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, Zymeworks Inc. (ZYME) is listed under Biotechnology. The $2.02B market capitalization puts ZYME squarely in mid-cap range for its industry. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies; and ProTECT, a tumor-specific immune co-stimulation platform.
Market Cap
$2.02B
Beta
1.17
P/E (TTM)
—
P/E (Fwd)
31.26
EPS (TTM)
$-2.02
EPS (Fwd)
$0.90
ROE
-72.3%
ROA
-24.1%
Cash
$270.7M
Total Debt
$16.0M
Free CF
-$65.1M
52W Change
52.8%
Annual Financials
Cash vs Debt
Where ZYME stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, ZYME finished 0.04% above its 150-day moving average ($25.53) and 2.00% above its 200-day moving average ($25.04). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ZYME overbought or oversold?
At the October 20, 2026 close, ZYME's RSI(14) was 41.3, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Zymeworks Inc. holds $270.7M in cash against $16.0M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$65.1M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -72.3% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has been uneven over recent years, ranging from $412.5M to $106.0M.
With cash comfortably exceeding debt, ZYME has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing ZYME's risk profile alongside its fundamentals and technical indicators provides a more complete picture.